Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 1 Precancerous Conditions 1 Pancreatic Neoplasms 1 Lymphoma, Follicular 1 Keratosis, Actinic 1 Breast Neoplasms 1

Interventions

Rituximab 130 Cyclophosphamide 113 Peripheral Blood Stem Cell Transplantation 59 fludarabine phosphate 55 Etoposide 47 Mycophenolic Acid 44 Radiotherapy 41 Filgrastim 41 Tacrolimus 40 Whole-Body Irradiation 36 Busulfan 34 Melphalan 33 Cyclosporine 30 Cytarabine 29 Methotrexate 28 sargramostim 27 Vincristine 27 Antilymphocyte Serum 27 Prednisone 26 Lenalidomide 23 obinutuzumab 22 Doxorubicin 22 Carmustine 21 Bortezomib 20 Methylprednisolone 19 fludarabine 17 Dexamethasone 17 Bendamustine Hydrochloride 17 ibritumomab tiuxetan 15 Cord Blood Stem Cell Transplantation 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Lymphoma, Follicular × perillyl alcohol × Clear all

NCT05023018 2026-03-02

NEO100 and High-Grade Meningioma

Neonc Technologies, Inc.

Phase 2 Recruiting

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡